[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580381":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":24,"locations":29,"responsibleParty":67,"collaborators":20,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":20,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":20,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Vanda Pharmaceuticals","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Open Label Tradipitant","EXPERIMENTAL","Oral Capsule",[13],"Drug: Tradipitant",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Tradipitant","BID",[9],null,[22],{"name":5,"affiliation":5,"role":23},"STUDY_DIRECTOR",[25],{"name":5,"role":26,"phone":27,"phoneExt":20,"email":28},"CONTACT","202-734-3400","clinicaltrials@vandapharma.com",[30,45,55],{"facility":31,"status":32,"city":33,"state":20,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Vanda Investigational Site","RECRUITING","Leuven","3000","Belgium","BE",{"type":38,"coordinates":39},"Point",[40,41],4.70093,50.87959,{"lat":41,"lon":40},[44],{"name":20,"role":26,"phone":27,"phoneExt":20,"email":20},{"facility":31,"status":32,"city":46,"state":20,"zip":47,"country":35,"countryCode":36,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"Liège","4000",{"type":38,"coordinates":49},[50,51],5.56749,50.63373,{"lat":51,"lon":50},[54],{"name":20,"role":26,"phone":27,"phoneExt":20,"email":20},{"facility":31,"status":32,"city":56,"state":20,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Leipzig","04103","Germany","DE",{"type":38,"coordinates":61},[62,63],12.37129,51.33962,{"lat":63,"lon":62},[66],{"name":20,"role":26,"phone":27,"phoneExt":20,"email":20},{"type":68,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100580381","phase-3-open-label-safety-study-of-tradipitant-in-idiopathic-and-diabetic-gastroparesis-100580381",false,"NCT06836557","Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis","A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis","Inclusion Criteria:\n\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Body Mass Index (BMI) of ≥18 and ≤40 kg\u002Fm2\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits\n* Pregnancy or nursing\n* Evidence of uncontrolled blood glucose (including HbA1C \\>11% at screening or metabolic crisis in past 60 days)","ALL","18 Years","70 Years",{"count":80,"type":81},100,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.",[87,88,89],"Idiopathic Gastroparesis","Diabetic Gastroparesis","Gastroparesis",[91,92,93,94,95,96,97,98,99,100,101,102],"gastroparesis","idiopathic","diabetic","tradipitant","nausea","vomiting","stomach","motility","functional","NK-1 antagonist","neurokinin 1 receptor","substance p","2025-02-14",{"date":105,"type":106},"2025-02-20","ACTUAL",{"date":108,"type":106},"2024-01-09",{"date":110,"type":81},"2025-12",{"name":5,"class":6},3]